Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 1/20 | 0.43 |
| ▸ | CBX7 | O95931 | 2/20 | 0.42 |
| ▸ | CDYL2 | Q8N8U2 | 2/20 | 0.42 |
| ▸ | CDYL | Q9Y232 | 2/20 | 0.42 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 1/20 | 0.39 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | POLR1A | O95602 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3939589 | 0.89 | KMT2A (0.40) | ACKR3CBX7CDYL2CDYLCDY1; CDY1B | |
| SCHEMBL19009679 | 0.82 | ALDH1A1 (0.44) | ACKR3CBX7CDYL2CDYLCDY1; CDY1B | |
| SCHEMBL7970805 | 0.81 | ACKR3 (0.43) | ACKR3CBX7CDYL2CDYLCDY1; CDY1B | |
| SCHEMBL19000005 | 0.78 | ACKR3 (0.41) | ACKR3CBX7CDYL2CDYLCDY1; CDY1B | |
| SCHEMBL19652207 | 0.78 | ACKR3 (0.41) | ACKR3CBX7CDYL2CDYLCDY1; CDY1B | |
| SCHEMBL26343464 | 0.78 | ACKR3 (0.53) | ACKR3CBX7CDYL2CDYLCDY1; CDY1B | |
| SCHEMBL425964 | 0.78 | L3MBTL3 (0.56) | CDYLCDY1; CDY1BL3MBTL3KMT2AMAPT | |
| SCHEMBL27788065 | 0.77 | MCHR1 (0.42) | ACKR3CBX7CDYL2CDYLKMT2A | |
| SCHEMBL3399163 | 0.76 | KMT2A (0.41) | ACKR3CBX7CDYL2CDYLCDY1; CDY1B | |
| SCHEMBL3507064 | 0.76 | KMT2A (0.41) | ACKR3CBX7CDYL2CDYLCDY1; CDY1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044083-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. (US) | 2009-04-08 | — | — | EP | claimed |
| US-20080051384-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. | 2008-02-28 | — | — | US | claimed |
| WO-2008008912-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. (US) | 2008-01-17 | — | — | WO | claimed |
| WO-2008008907-A2 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. (US) | 2008-01-17 | — | — | WO | claimed |
| EP-1844042-A1 | INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2007-10-17 | — | — | EP | claimed |
| US-20060211698-A1 | Bicyclic heteroaryl derivatives for treating viruses | GENELABS, INC. | 2006-09-21 | — | — | US | claimed |
| WO-2006076529-A1 | INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2006-07-20 | — | — | WO | claimed |
| EP-2049536-A2 | POLYCYCLIC VIRAL INHIBITORS | GENELABS TECHNOLOGIES, INC. (US) | 2009-04-22 | — | — | EP | disclosed |
| EP-2044083-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. (US) | 2009-04-08 | — | — | EP | disclosed |
| US-20080051384-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. | 2008-02-28 | — | — | US | disclosed |
| US-20080045498-A1 | POLYCYCLIC VIRAL INHIBITORS | GENELABS TECHNOLOGIES, INC. | 2008-02-21 | — | — | US | disclosed |
| WO-2008011521-A2 | POLYCYCLIC VIRAL INHIBITORS | GENELABS TECHNOLOGIES, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008008912-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008008907-A2 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| EP-1844042-A1 | INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2007-10-17 | — | — | EP | disclosed |
| US-20060211698-A1 | Bicyclic heteroaryl derivatives for treating viruses | GENELABS, INC. | 2006-09-21 | — | — | US | disclosed |
| WO-2006076529-A1 | INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2006-07-20 | — | — | WO | disclosed |
| EP-0863897-A1 | 5-PHENYL-3-(PIPERIDIN-4-YL)-1,3,4-OXADIAZOL-2(3H)-ONE DERIVATIVES FOR USE AS 5-HT 4? OR H 3? RECEPTOR LIGANDS | SYNTHELABO (FR) | 1998-09-16 | — | — | EP | disclosed |
| WO-1997017345-A1 | 5-PHENYL-3-(PIPERIDIN-4-YL)-1,3,4-OXADIAZOL-2(3H)-ONE DERIVATIVES FOR USE AS 5-HT4 OR H3 RECEPTOR LIGANDS | SYNTHELABO (FR) | 1997-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045498-A1 | POLYCYCLIC VIRAL INHIBITORS | EIF2AK2, ZC3HAV1, MAVS | ACKR3 3347/4885CBX7 555/4885CDYL2 3419/4885 |
| US-20060211698-A1 | Bicyclic heteroaryl derivatives for treating viruses | HAVCR2, ZC3HAV1, SARS1 | ACKR3 2133/4885CBX7 400/4885CDYL2 2810/4885 |
| US-20080051384-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | ACKR3 2983/4885CBX7 2500/4885CDYL2 4283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.